Outcome | Non-responders n = 3 | Relapsers n = 3 | Responders n = 92 | Intolerant n = 9 | P value | |
---|---|---|---|---|---|---|
Laboratory result | ||||||
Hemoglobin (HGB) concentration (gm/dl) | Baseline | 13.3 ± 2.3 | 12.73 ± 1.11 | 12.17 ± 1.6 | 11.36 ± 1.32 | P = 0.26 |
End of treatment | 12.07 ± 0.31 | 12.13 ± 0.38 | 11.2 ± 1.5 | P = 0.36 | ||
White blood cell count (WBCs) (*103/μl) | Baseline | 3.3 ± 0.36 | 5.7 ± 2.1A | 4.66 ± 1.6B | 3.26 ± 1.12AB | P = 0.02 |
End of treatment | 3.67 ± 0.23 | 5.0 ± 1.8 | 4.65 ± 1.7 | P = 0.58 | ||
platelet count (PLTs) (*103/μl) | Baseline | 58 (58–100) | 84 (74–111) | 94.5 (50–356) | 111 (55–142) | P = 0.39 |
End of treatment | 57 (43–138) | 105 (100–170) | 104 (37–392) | P = 0.32 | ||
Serum creatinine (mg/dl) | Baseline | 0.6 ± 0.1A | 0.87 ± 0.4 | 0.85 ± 0.25B | 1.17 ± 0.4AB | P = 0.003 |
End of treatment | 0.78 ± 0.09 | 0.85 ± 0.07 | 0.89 ± 0.37 | P = 0.86 | ||
ALT/ULN (folds) | Baseline | 1.05 (0.78–4.12) | 1.03 (0.8–1.24) | 1.325 (0.22–5.35) | 0.93 (0.48–2.85) | P = 0.13 |
End of treatment | 0.4 (0.4–1.29) | 1.0 (0.88–1.05) | 0.67 (0.2-2) | P = 0.13 | ||
AST/ULN (folds) | Baseline | 1.62 (1.03–4.7) | 1.85 (1.38–3.41) | 1.765 (0.46–5.85) | 1.73 (0.4–3.46) | P = 0.9 |
End of treatment | 0.55 (0.48–2.27) | 0.86 (0.6–1.43) | 0.9 (0.25–7) | P = 0.77 | ||
Albumin level (gm/dl) | Baseline | 3.0 ± 0.26 | 2.53 ± 0.25 | 2.89 ± 0.4 | 2.8 ± 0.24 | P = 0.32 |
End of treatment | 3.5 ± 0.2 | 3.1 ± 0.14 | 3.23 ± 0.48 | P = 0.87 | ||
Serum bilirubin (mg/dl) | Baseline | 1.77 ± 0.6 | 2.3 ± 0.79 | 1.42 ± 0.7 | 1.54 ± 1.0 | P = 0.23 |
End of treatment | 1.35 ± 0.07 | 2.13 ± 1.07 | 1.29 ± 0.7 | P = 0.17 | ||
I.N.R. | Baseline | 1.42 ± 0.28 | 1.42 ± 0.14 | 1.32 ± 0.22 | 1.3 ± 0.18 | P = 0.72 |
End of treatment | 1.39 ± 0.15 | 1.32 ± 0.0 | 1.38 ± 0.25 | P = 0.97 | ||
AFP (μg/l) | Baseline | 12.0 (6.5–83) | 10.2 (9.0–20.7) | 12.35 (0.1–201) | 7.6 (2.64–25) | P = 0.51 |
End of treatment | 4.8 (4.8–4.8) | 8.15 (6.7–9.6) | 5.7 (0.2–24) | P = 0.49 |